Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.

ABSTRACT:

Background

In the USA, chronic kidney disease (CKD) affects 1 in 7 adults and costs $100 billion annually. The DAPA-CKD trial found dapagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, to be effective in reducing CKD progression and mortality in patients with diabetic and non-diabetic CKD. Currently, SGLT2 inhibitors are not considered standard of care for patients with non-diabetic CKD.

Objective

Determine the cost-effectiveness of adding dapagliflozin to standard management of patients with non-diabetic CKD.

Design

Markov model with lifetime time horizon and US healthcare sector perspective.

Patients

Patients with non-diabetic CKD INTERVENTION: Dapagliflozin plus standard care versus standard care only.

Main measures

Quality-adjusted lif

SUBMITTER: Tisdale RL 

PROVIDER: S-EPMC9551016 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature